Zydus Lifesciences gains 2%, hits 52-week high

Zydus Lifesciences gains 2%, hits 52-week high in weak market; here's why SEBI RA – Shubh Consultancy – Sunil Kotak – INH000015826

Zydus Lifesciences share price movement Zydus Lifesciences' share price hit a 52-week high of ₹1,228.25, gaining 2 per cent on the BSE in Monday’s intra-day deals in an otherwise weak market after the company said it concluded an onsite United States Food and Drug Administration (USFDA) inspection of its pharmacovigilance and post-marketing surveillance system at its New Jersey, USA office. The inspection concluded with 'NIL' observations. At 11:05 AM, Zydus Lifesciences quoted 1.8 per cent higher at ₹1,223.50, compared to a 1.4 per cent dip in the BSE Sensex. The average trading volume at the counter jumped nearly two-fold with a combined 2.06 million shares changing hands on the NSE and BSE What’s driving Zydus's 47% rebound from the March low? Shares of the pharmaceutical company Zydus Lifesciences bounced back 47 per cent from its 52-week low of ₹835.85 touched on March 2, 2026. The stock is inching toward its record high of ₹1,323.90 touched on August 9, 2024. Zydus group is in the branded generics market in India and is expected to benefit from growth in the wellness segment. The group has strong positions across cardio-diabetology, respiratory, oncology, gynaecology and nephrology, supported by an established brand portfolio and wide physician reach. Continued traction in chronic and super-specialty therapies, sustained traction in innovation products such as Saroglitazar and Desidustat, and biosimilars and vaccines should support growth above the Indian pharmaceutical market over the medium term. All this is for information This is not a buy/sell recommendation. Thank you, Technofunda24